1 ASX RELEASE 8 October 2026 Further Obsidian Note Redemption and Phase 3 Data Review Update Paradigm Biopharmaceuticals Limited (Administrators Appointed) (ASX: PAR) (“Paradigm” or “the Company”) advises that, following discussions with Obsidian Global GP, LLC (“Obsidian”), the parties...